01:02pm

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)					Complete if Known				
					Application Number		10/757,632		
					Filing Date		January 14, 2004		
					First Named I	nventor	Herbert W. Virgin		
					Art Unit		1648		
					Examiner Nam	c	Stacy Brown Chen		
Sheet 1 of 1					Attorney Dock	et Number	60005161-0168		
			OTHER	ITEMS - NON PATE	NT LITERATUR	E DOCUME	NTS		
Examiner Cite Include name of the author (in CAPITAL item (book, magazine, journal, serial, sym					LETTERS), title of the anicle (when appropriate), title of the appropriate), title of the appropriate), title of the appropriate), volume-issue number(s), y and/or country where published.			T²	
SAC	l	BALL et al., "Oral Immunization with Recombinant Norwalk Virus-Like Particles Induces a Systemic and Mucosal Immune Response in Mice," J. Virol., 1998, pp. 1345-1353, Vol. 72.							
	2	GEISSLER et al., "Feline Calicivirus Capsid Protein Expression and Capsid Assembly in Cultured Feline Cells," J. Virol., 1999, pp. 834-838, Vol. 73.							
	3	GREEN et al., "Comparison of the Reactivities of Baculovirus-Expressed							
		Recombinant Norwalk Virus Capsid Antigen with Those of the Native Norwalk							
		Virus Antigen in Serologic Assays and Some Epidemiologic Observations," J. Clin. Microbiol., 1993, pp. 2185-2191, Vol. 31.							
	4	GREEN et al., "Expression and Self-Assembly of Recombinant Capsid Protein							
	from the Antigenically Distinct Hawaii Human Calivirus," J. Clin. Micro 1997, pp. 1909-1914, Vol. 35.								
	5 GUERRERO et al., "Recombinant Norwalk Virus-Lik						Particles Administered		
		Intranasally to Mice Induce Systemic and Mucosal (Fecal and Vaginal) Immune							
	6	Responses," J. Virol., 2001, pp. 9713-9722, Vol. 75.  JIANG et al., "Baculovirus Expression and Antigenic Characterization of the							
		Capsid Proteins of Three Norwalk-Like Virus," Archives of Virol., 2002, pp. 119-130, Vol. 147.  JIANG et al., "Expression, Self-Assembly, and Antigenicity of the Norwalk Virus Capsid Protein," J. Virol., 1992, pp. 6527-5532, Vol. 66.							
	7								
	8	LIANG Novel E	G et al., "Protection Against Fatal Sindbis Virus Encephalitis by Beclin, a l Bet-2-Interacting Protein," J. Virol., 1998, pp. 8586-8696, Vol. 72.						
	9	PELOSI et al., "The Seroepidemiology of Genogroup 1 and Genogroup 2 Norwalk- Like Viruses in Italy," J. Med. Virol., 1999, pp. 93-99, Vol. 58							
	10	PRASAD et al., "Structural Studies of Recombinant Norwalk Capsids." I Infect							
Dis., 2000, pp. 8317-8321, Vol. 181.								ı	
A	WHITE et al., "Attachment and Entry of Recombinant Norwalk Virus Capsids to Cultured Human and Animal Cell Lines," J. Virol., 1996, pp. 6589-6597, Vol. 70.								
Examine	r Sign	ature	Stal	y B. Cher		Date Cons			

<sup>\*</sup>EXAMINER: tritial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chilaf Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1540, Alexandria, VA 22113-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

hs are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction act of 1995, no pe Complete if Known Substitute for form 1449B/PTO 10/757.832 **Application Number** INFORMATION DISCLOSURE January 14, 2004 Filing Date STATEMENT BY APPLICANT Herbert W. Virgin First Named Inventor 1648 Art Unit Stacy Brown Chen (use as many sheets as necessary) **Examiner Name** 60005161-0168 of Sheet 1 Attorney Docket No. OTHER ITEMS - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the T<sup>2</sup> Examiner item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), No.1 Initials\* publisher, city and/or country where published. KARST et al., "STAT1-Dependent Innate Immunity to a Norwalk-Like Virus," 12 Science, 2003, pp. 1575-1578, Vol. 299. **Date Considered** Hay B. Char

Examiner Signature

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1540, Alexandria, VA 22113-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.